ABSTRACT Thirty one children with asthma were given 40 jug of ipratropium bromide and identical placebo by inhalation three times a day in a double blind, randomised crossover study to test the ability of an anticholinergic drug to modify the diurnal variation in airway calibre and bronchial reactivity. Subjects measured peak expiratory flow rate approximately eight hourly, before and after inhaled salbutamol, for four week periods. Paired t tests and cosinor analysis were used to assess the diurnal variation in airway calibre from the peak expiratory flow rate recorded before salbutamol and to assess the diurnal variation in bronchodilator responsiveness from the increase in peak expiratory flow rate after salbutamol. Maintenance treatment with ipratropium bromide 40 ig three times daily reduced the provocative dose of histamine which caused a 20% fall in FEV1 (geometric mean PD20 = 0-78 v 0-49 mg/ml, p < 0 05), despite an eight to 12 hour gap between the last dose of ipratropium and histamine challenge. It did not, however, diminish the diurnal variation in airway calibre (mean amplitude = 12-7 v 10 1) or in bronchodilator responsiveness (mean amplitude = 62-4 v 63 5). There was no improvement in the clinical state of subjects while they were taking ipratropium bromide.
A diurnal variation in airway calibre, as judged by peak expiratory flow (PEF), has been described in adults with asthma' and children with asthma.2 3 The mechanisms underlying this rhythm are unknown.
Diurnal variation in airway sensitivity to histamine4 and to acetylcholine' has also been described and could not be explained by variation in baseline airway calibre. The mechanisms underlying this diurnal variation in airway sensitivity are not known. Bronchoconstriction after inhalation of histamine is thought to be mediated in part by vagal reflexes.6
Thus the diurnal variation in airway sensitivity to histamine, and other substances, may also be mediated in part through the vagus.
Nocturnal exacerbations of asthma have been attributed to an exaggeration of the diurnal variation (11 9) , and 29 (16-2) respectively for the ipratropium bromide period.
DIARY CARDS
There were no differences in symptom scores or additional doses of salbutamol during the baseline, ipratropium bromide, or placebo periods (table 2) . No child was able to reduce maintenance treatment while taking ipratropium bromide.
Discussion
Treatment with ipratropium bromide (40pg) caused no change in mean PEF values in the 31 children who took part in this study, and it failed to modify the diurnal variation in airway calibre or in bron-. chodilator responsiveness to salbutamol. Nor did it reduce symptom scores or decrease the use of additional doses of salbutamol. 
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In previous reports it has been suggested that ipratropium bromide may decrease the diurnal variation in PEF.9 10 The results of this study do not support this suggestion. The reasons for the difference between the results of this study and those in previous reports are not obvious. Mann and Hiller,9 who also studied children, used the same dosage regimen of ipratropium bromide as we did, and measurements were also made three times a day. They did not examine the diurnal variation in PEF directly but they found significantly higher mean PEF values in the morning with ipratropium bromide. Evening PEF recordings were also higher with ipratropium bromide but the increase was not significant. In the present study the effect of ipratropium bromide was assessed in each subject by comparing morning and afternoon PEF values each day using Dunnett's paired t test. Mann and Hiller9 appear to have used a paired t test on the group as a whole, comparing only the mean value of morning and evening PEF for each subject. In the present study eight children had significantly higher morning PEF values when taking ipratropium but only four of these had lower amplitudes of the diurnal variation in PEF while taking ipratropium. This suggests that simply comparing mean morning and evening (or afternoon) PEF values on and off a treatment for a group as a whole may not be the best way to evaluate the effect of that medication on the diurnal variation in PEF.
Maintenance treatment with clinically acceptable doses of ipratropium bromide did not result in clinical improvement in the children in this study. Most reported symptoms of asthma during the study and most required additional doses of salbutamol. Ipratropium bromide treatment did not reduce symptom scores or result in the use of fewer additional doses of salbutamol. These results, coupled with the failure of ipratropium bromide to decrease the amplitude of the diurnal variation in airway calibre or in bronchodilator responsiveness, do not support the use of ipratropium bromide as an additional treatment for children with asthma. The subjects in this study were clinically stable, and it is possible that a different result may have been found in children with unstable asthma.
The failure of ipratropium bromide to modify the amplitudes of the diurnal variations in airway calibre or in bronchodilator responsiveness suggests that these rhythms are not vagally mediated. Ipratropium bromide can cause vagal efferent blockade in man."3 14 A dose of 40 pg three times daily has been reported to cause bronchodilatation in children9 13 14 and to blunt the response to experimental bronchoconstriction.13 14 The bronchodilator effect of Sly, Landau, Olinsky ipratropium bromide peaks one hour after inhalation and virtually disappears within six hours.13 The failure of ipratropium bromide to diminish the diurnal variation in airway calibre and in bronchodilator responsiveness may be because its anticholinergic action does not last long enough to be effective in an eight hourly regimen. The small but significant increase in PD20 seen after treatment with ipratropium bromide, despite an eight to 12 hour gap between the last dose of ipratropium bromide and the histamine challenge test, suggests, however, that the anticholinergic action of ipratropium bromide may last longer than its detectable bronchodilator action.
